Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Adoption of Companion Animals, such as Dogs and Cats
4.2.2 Increasing Cases of Zoonotic Diseases
4.3 Market Restraints
4.3.1 High Cost of Vaccine Development and Regulatory Concern
4.4 Industry Attractiveness - Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value - in USD Millions)
5.1 By Technology
5.1.1 Live Attenuated Vaccines
5.1.2 Inactivated Vaccines
5.1.3 Toxoid Vaccines
5.1.4 Recombinant Vaccines
5.1.5 Other Technologies
5.2 By Animal Type
5.2.1 Dogs
5.2.2 Cats
5.2.3 Other Animal Types
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 COMPANY PROFILES
6.1.1 Elanco Animal Health Incorporated
6.1.2 Boehringer Ingelheim GmbH
6.1.3 Brilliant Bio Pharma
6.1.4 Merck & Co. Inc.
6.1.5 Virbac
6.1.6 Zoetis Inc.
6.1.7 Indian Immunologicals Ltd
6.1.8 Bioveta AS
6.1.9 Durvet Inc.
6.1.10 HIPRA
6.1.11 Phibro Animal Health Corporation
6.1.12 Hester Biosciences Limited


7 MARKET OPPORTUNITIES AND FUTURE TRENDS